2021
Prognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights From 3 Large Prospective Cohorts
Akintoye E, Afonso L, Jayanna M, Bao W, Briasoulis A, Robinson J. Prognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights From 3 Large Prospective Cohorts. Journal Of The American Heart Association 2021, 10: e019589. PMID: 34092110, PMCID: PMC8477885, DOI: 10.1161/jaha.120.019589.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmerican Heart AssociationBiomarkersCardiovascular DiseasesCholesterolClinical Decision-MakingCoronary Artery DiseaseDecision Support TechniquesDyslipidemiasFemaleHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleMiddle AgedPractice Guidelines as TopicPredictive Value of TestsPrimary PreventionPrognosisRisk AssessmentTime FactorsUnited StatesVascular CalcificationConceptsPooled Cohort EquationsCoronary artery calcium scoreCholesterol treatment guidelinesArtery calcium scoreAtherosclerotic cardiovascular diseaseCohort EquationsRisk enhancersCalcium scoreTreatment guidelinesCardiovascular diseaseAmerican Heart Association/American CollegeAtherosclerotic cardiovascular disease eventsBackground Limited dataIntermediate-risk participantsIntermediate-risk patientsCardiovascular disease eventsLarge prospective cohortIncremental valueNet reclassification indexStatin therapyCAC testingProspective cohortPrognostic utilityC-statisticReclassification index
2018
Racial/ethnic differences in the prognostic utility of left ventricular mass index for incident cardiovascular disease
Akintoye E, Mahmoud K, Shokr M, Sandio A, Mallikethi‐Reddy S, Sheikh M, Adegbala O, Egbe A, Briasoulis A, Afonso L. Racial/ethnic differences in the prognostic utility of left ventricular mass index for incident cardiovascular disease. Clinical Cardiology 2018, 41: 502-509. PMID: 29663526, PMCID: PMC6490106, DOI: 10.1002/clc.22914.Peer-Reviewed Original ResearchMeSH KeywordsAgedAsianBlack or African AmericanCardiovascular DiseasesComorbidityDatabases, FactualDisease ProgressionFemaleHispanic or LatinoHumansHypertrophy, Left VentricularIncidenceMagnetic Resonance Imaging, CineMaleMiddle AgedPredictive Value of TestsPrognosisProportional Hazards ModelsRacial GroupsRisk FactorsTime FactorsUnited StatesVentricular Function, LeftVentricular RemodelingWhite PeopleConceptsLeft ventricular mass indexLeft ventricular hypertrophyNon-Hispanic whitesVentricular mass indexCVD eventsIncident CVDMass indexPrognostic utilityEthnic differencesFuture cardiovascular disease eventsOptimal cutpointCardiovascular disease eventsFuture CVD eventsIncident cardiovascular diseaseRisk stratification strategiesIncident cardiovascular outcomesMulti-Ethnic StudyRace/ethnicityCardiovascular outcomesLVMI valuesVentricular hypertrophyCardiovascular diseaseDisease eventsCox modelStratification strategies
2017
Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery
Akintoye E, Sellke F, Marchioli R, Tavazzi L, Mozaffarian D. Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery. Journal Of Thoracic And Cardiovascular Surgery 2017, 155: 242-251.e10. PMID: 28890081, DOI: 10.1016/j.jtcvs.2017.07.063.Peer-Reviewed Original ResearchConceptsPostoperative atrial fibrillationMajor adverse cardiovascular eventsCoronary artery bypassAdverse cardiovascular eventsArtery bypassAtrial fibrillationCardiovascular eventsCardiac surgeryHigh riskConcomitant valvularValvular surgeryCardiopulmonary bypassAdverse outcomesVentricular pacingBypass useCoronary artery bypass graft surgeryConcomitant coronary artery bypassArtery bypass graft surgeryBypass graft surgeryMultivariable-adjusted modelsCardiopulmonary bypass useType of surgeryData of patientsSpecific adverse outcomesSurgery characteristics
2016
Novel biomarkers with potential for cardiovascular risk reclassification
Mallikethi-Reddy S, Briasoulis A, Akintoye E, Afonso L. Novel biomarkers with potential for cardiovascular risk reclassification. Biomarkers 2016, 22: 189-199. PMID: 27299923, DOI: 10.1080/1354750x.2016.1201540.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCardiovascular DiseasesCystatin CErythrocyte IndicesFemaleHomocysteineHumansMaleRisk AssessmentConceptsRed cell distribution widthCardiovascular risk reclassificationRisk reclassificationNovel risk markersCardiovascular risk predictionCell distribution widthCardiovascular riskCVD eventsMultivariate risk modelIntermediate riskAbsolute riskAsymptomatic individualsSerum biomarkersRisk markersTreatment recommendationsRisk factorsCystatin CNovel biomarkersRisk modelDistribution widthBiomarkersRisk predictionPatientsRiskReclassification